Dr. Lisa Barroilhet
Claim this profileUniversity of Wisconsin Carbone Cancer Center
Studies Ovarian Cancer
Studies Adenocarcinoma
15 reported clinical trials
28 drugs studied
Area of expertise
1Ovarian Cancer
Stage III
Stage IV
BRCA1 positive
2Adenocarcinoma
Stage III
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Lisa Barroilhet is currently running
Letrozole +/- Chemotherapy
for Ovarian Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.
Recruiting2 awards Phase 318 criteria
Peposertib + Chemotherapy
for Ovarian Cancer
This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a period of improvement (recurrent). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving peposertib and pegylated liposomal doxorubicin hydrochloride may work better in treating patients with ovarian cancer compared to pegylated liposomal doxorubicin hydrochloride alone.
Recruiting1 award Phase 124 criteria
More about Lisa Barroilhet
Clinical Trial Related5 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Lisa Barroilhet has experience with
- Paclitaxel
- Pegylated Liposomal Doxorubicin Hydrochloride
- Minimally Invasive Surgery
- Chemotherapy
- Laparotomy
- VB-111
Breakdown of trials Lisa Barroilhet has run
Ovarian Cancer
Adenocarcinoma
Ovarian Tumors
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lisa Barroilhet specialize in?
Lisa Barroilhet focuses on Ovarian Cancer and Adenocarcinoma. In particular, much of their work with Ovarian Cancer has involved Stage III patients, or patients who are Stage IV.
Is Lisa Barroilhet currently recruiting for clinical trials?
Yes, Lisa Barroilhet is currently recruiting for 4 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Lisa Barroilhet has studied deeply?
Yes, Lisa Barroilhet has studied treatments such as Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Minimally Invasive Surgery.
What is the best way to schedule an appointment with Lisa Barroilhet?
Apply for one of the trials that Lisa Barroilhet is conducting.
What is the office address of Lisa Barroilhet?
The office of Lisa Barroilhet is located at: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53792 United States. This is the address for their practice at the University of Wisconsin Carbone Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.